Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) trades at $22.44. The Direxion Daily Pharmaceutical & Medical Bull 3X ETF aims for 300% of the daily performance of the S&P Pharmaceuticals Select Industry… Market cap: $46.5M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for PILL: PILL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PILL against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on PILL.
How is this calculated? →Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) Financial Services Profile
Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) is a leveraged exchange-traded fund seeking to magnify the daily performance of the S&P Pharmaceuticals Select Industry Index by 300%. As a leveraged ETF, PILL is designed for short-term trading and carries substantial risk due to market volatility.
What Is the Investment Thesis for PILL?
PILL offers a high-risk, high-reward proposition for investors seeking short-term exposure to the pharmaceutical and medical sectors. As a leveraged ETF, its value is tied to the daily performance of the S&P Pharmaceuticals Select Industry Index, magnified by a factor of three. The fund's appeal lies in its potential to generate outsized returns in a rapidly rising market. However, this leverage also amplifies losses, making it unsuitable for risk-averse investors or those with a long-term investment horizon. The fund's performance is highly sensitive to market volatility and the daily rebalancing process, which can erode returns over time. With a market cap of $46.5M and a beta of 2.11, PILL exhibits significant volatility and is best used as a tactical tool for short-term trading strategies.
Based on FMP financials and quantitative analysis
PILL Key Highlights
PILL seeks daily investment results of 300% of the S&P Pharmaceuticals Select Industry Index.
- The fund is designed for short-term trading and is not intended for long-term investment.
- PILL's leveraged structure amplifies both gains and losses, making it a high-risk investment.
- The fund's daily rebalancing can lead to performance deviations over longer periods due to compounding.
- PILL has a beta of 2.11, indicating higher volatility compared to the broader market.
Who Are PILL's Competitors?
PILL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BUYO KraneShares Man Buyout Beta Index ETF | $33.49 | -0.94% | $17.0M | 44 |
| CGRO CoreValues Alpha Greater China Growth ETF | $22.51 | -0.81% | $8.89M | 44 |
| FSBD FIDELITY SUSTAINABLE CORE PLUS BOND ETF | $47.77 | -0.13% | $13.1M | — |
| INOV Innovator International Developed Power Buffer ETF - November | $37.78 | -0.16% | $37.8M | 55 |
| JUNZ TrueShares Structured Outcome (June) ETF | $35.74 | -0.46% | $30.9M | 44 |
| EEA The European Equity Fund, Inc. | $11.15 | -0.59% | $74.7M | 67 |
| HNNA Hennessy Advisors, Inc. | $9.89 | -1.30% | $78.2M | 81 |
| BCG Binah Capital Group, Inc. | $1.40 | +0.72% | $23.5M | 78 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PILL's Key Strengths?
Leveraged exposure to the pharmaceutical and medical sectors.
- Potential for amplified returns in a rising market.
- Caters to short-term trading strategies.
- Brand recognition of Direxion ETFs.
What Are PILL's Weaknesses?
High risk due to leveraged structure.
- Potential for significant losses in a declining market.
- Performance deviations over longer periods due to daily rebalancing.
- Not suitable for long-term investment.
What Could Drive PILL Stock Higher?
PILL catalyst: Clinical trial results for major pharmaceutical companies within the S&P Pharmaceuticals Select Industry Index could drive short-term price movements.
- Regulatory approvals for new drugs and medical devices can positively impact the performance of the underlying index.
- Mergers and acquisitions within the healthcare sector can create volatility and trading opportunities for PILL.
What Are the Key Risks for PILL?
Market corrections in the pharmaceutical and medical sectors could lead to significant losses for PILL investors.
- The fund's leveraged structure amplifies both gains and losses, making it a high-risk investment.
- Daily rebalancing can lead to performance deviations over longer periods due to compounding.
- Regulatory changes impacting the healthcare industry could negatively affect the performance of the underlying index.
- Economic downturns could reduce investor sentiment and trading activity in the healthcare sector.
What Are the Growth Opportunities for PILL?
- Increased Volatility in Healthcare Sector: Market volatility within the pharmaceutical and healthcare sectors presents opportunities for PILL to generate amplified returns. As the S&P Pharmaceuticals Select Industry Index experiences fluctuations due to factors such as clinical trial results, regulatory changes, and market sentiment, PILL's 3x leverage can potentially lead to significant gains for short-term traders. However, increased volatility also increases the risk of substantial losses. This growth opportunity is ongoing, contingent on the continued dynamism of the healthcare industry.
- Short-Term Trading Strategies: PILL's design caters to investors employing short-term trading strategies. Day traders and those seeking to capitalize on intraday price movements in the pharmaceutical and medical sectors may find PILL an attractive tool. The fund's leveraged structure allows for potentially higher percentage gains compared to traditional ETFs, albeit with increased risk. The timeline for this growth opportunity is immediate and dependent on the investor's trading expertise and market timing.
- Rising Interest in Leveraged ETFs: The growing popularity of leveraged ETFs among sophisticated investors presents a growth opportunity for PILL. As more traders seek to amplify their returns through leveraged products, PILL could attract increased trading volume and assets under management. However, this growth is contingent on educating investors about the risks associated with leveraged ETFs and ensuring responsible usage. The timeline for this growth opportunity is medium-term, influenced by investor education and market trends.
- Product Innovation in Healthcare: Breakthroughs and innovations within the pharmaceutical and medical industries can drive positive sentiment and stock price appreciation, benefiting PILL. New drug approvals, advancements in medical technology, and positive clinical trial results can lead to increased investor interest and trading activity in the sector. PILL's leveraged exposure allows investors to potentially capitalize on these positive developments. This growth opportunity is ongoing and dependent on the pace of innovation in healthcare.
- Geopolitical Events Impacting Healthcare: Geopolitical events, such as trade disputes, regulatory changes, and healthcare reforms, can create volatility and trading opportunities within the pharmaceutical and medical sectors. PILL's leveraged structure allows investors to potentially profit from short-term market reactions to these events. However, geopolitical risks also increase the potential for significant losses. This growth opportunity is event-driven and dependent on global political and economic developments.
What Are PILL's Competitive Advantages?
- Leveraged Exposure: PILL's primary competitive advantage is its 3x leveraged exposure to the S&P Pharmaceuticals Select Industry Index, offering the potential for amplified returns.
- Niche Market: PILL caters to a specific niche of investors seeking short-term, high-risk trading opportunities in the healthcare sector.
- Brand Recognition: Direxion is a well-known provider of leveraged and inverse ETFs, giving PILL brand recognition among traders.
What Does PILL Do?
The Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) is designed to provide traders with a leveraged investment vehicle to capitalize on short-term gains in the pharmaceutical and medical sectors. Launched with the objective of delivering three times the daily performance of the S&P Pharmaceuticals Select Industry Index, PILL offers an aggressive approach to investing in companies involved in pharmaceuticals, biotechnology, and healthcare equipment. The fund's strategy involves using financial instruments such as swaps, futures contracts, and other derivatives to amplify the returns of the underlying index. However, due to the effects of compounding, the fund's performance over periods longer than one day can significantly deviate from the 3x multiple of the index's return. PILL is not intended as a long-term investment and is best suited for sophisticated investors with a high-risk tolerance who actively monitor their positions. The fund's daily rebalancing and leveraged structure can lead to substantial losses, especially in volatile markets.
What Products and Services Does PILL Offer?
- Seeks daily investment results of 300% of the performance of the S&P Pharmaceuticals Select Industry Index.
- Provides leveraged exposure to the pharmaceutical and medical sectors.
- Utilizes financial instruments such as swaps and futures contracts to achieve its investment objective.
- Rebalances its portfolio daily to maintain its 3x leverage ratio.
- Offers a tool for short-term trading strategies in the healthcare industry.
- Allows investors to potentially amplify gains (and losses) based on the performance of the underlying index.
How Does PILL Make Money?
- PILL generates revenue through management fees charged to investors.
- The fund's expense ratio covers the costs of managing the portfolio and operating the fund.
- PILL's profitability is influenced by its assets under management and trading volume.
What Industry Does PILL Operate In?
The asset management industry is characterized by a diverse range of investment vehicles, including ETFs, mutual funds, and hedge funds. Leveraged ETFs like PILL cater to investors seeking to amplify returns through short-term trading strategies. The pharmaceutical and medical sectors are influenced by factors such as regulatory approvals, drug pricing, and technological advancements. PILL's performance is directly tied to the performance of companies within these sectors, making it sensitive to industry-specific news and events. The competitive landscape includes other leveraged ETFs and investment products offering exposure to the healthcare industry.
Who Are PILL's Key Customers?
- Short-term traders seeking leveraged exposure to the pharmaceutical and medical sectors.
- Sophisticated investors with a high-risk tolerance.
- Day traders and active portfolio managers.
- Investors looking to capitalize on short-term market movements.
Insider Activity
The most recent 11 insider filings for Direxion Daily Pharmaceutical & Medical Bull 3X ETF break down as 3 sales and 8 purchases. On net that is roughly 1.7M shares disposed (about $1.5M), a signal worth weighing alongside the fundamentals.
Key Financial Metrics
Return on equity for Direxion Daily Pharmaceutical & Medical Bull 3X ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. PILL trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
PILL Valuation & Market Position
With a $46.5M market cap, Direxion Daily Pharmaceutical & Medical Bull 3X ETF sits in the micro-cap segment of the market.
PILL Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the pharmaceutical sector's recovery, suggesting potential upside for PILL.
- Social sentiment has shifted positively as discussions around healthcare advancements have gained traction, boosting investor interest.
- Market perception is improving as new drug approvals and innovations are highlighted, potentially driving demand for ETFs like PILL.
- The overall trend in healthcare spending is rising, which may benefit pharmaceutical-focused funds, aligning with PILL's strategy.
Bear Case
- Concerns over rising interest rates are creating uncertainty in the broader market, which may negatively impact leveraged ETFs like PILL.
- Recent bearish sentiment in the community reflects apprehension about regulatory changes affecting the pharmaceutical industry.
- Market volatility has led to cautious trading behavior, with many investors wary of the risks associated with leveraged products like PILL.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PILL Latest News
No recent news available for PILL.
PILL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PILL.
Price Targets
Wall Street price target analysis for PILL.
PILL MoonshotScore
What does this score mean?
The MoonshotScore rates PILL 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Direxion Daily Pharmaceutical & Medical Bull 3X ETF Financial Services Stock: Key Questions Answered
What does Direxion Daily Pharmaceutical & Medical Bull 3X ETF do?
The Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) is a leveraged exchange-traded fund designed to deliver three times the daily performance of the S&P Pharmaceuticals Select Industry Index. It achieves this objective through the use of financial instruments such as swaps, futures contracts, and other derivatives.
What are the main risks for PILL?
The primary risk associated with PILL is its leveraged structure, which amplifies both gains and losses. A decline in the S&P Pharmaceuticals Select Industry Index can result in significant losses for PILL investors. Additionally, the fund's daily rebalancing process can lead to performance deviations over longer periods due to compounding.
How does Direxion Daily Pharmaceutical & Medical Bull 3X ETF make money in financial services?
Direxion Daily Pharmaceutical & Medical Bull 3X ETF generates revenue primarily through management fees charged to investors. These fees are calculated as a percentage of the fund's assets under management (AUM). The fund's profitability is directly linked to its AUM and trading volume. Higher AUM translates to increased management fee revenue.
What is Direxion Daily Pharmaceutical & Medical Bull 3X ETF's risk management approach?
As a leveraged ETF, Direxion Daily Pharmaceutical & Medical Bull 3X ETF's risk management primarily focuses on maintaining its 3x leverage ratio and managing the risks associated with its derivative positions. The fund employs a daily rebalancing strategy to ensure that its leverage remains consistent with its investment objective.
What are the key factors to evaluate for PILL?
Evaluate PILL on fundamentals, analyst consensus, and risk factors. PILL offers a high-risk, high-reward proposition for investors seeking short-term exposure to the pharmaceutical and medical sectors. Not financial advice.
How frequently does PILL data refresh on this page?
PILL's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PILL's recent stock price performance?
Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leveraged exposure to the pharmaceutical and medical sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PILL overvalued or undervalued right now?
Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for PILL. Information is based on available business descriptions and financial data.
- Leveraged ETFs are complex instruments and carry significant risk. Investors should consult with a financial advisor before investing.